Bone tumors are a rare and heterogeneous group of neoplasms that occur in the bone. The
diversity and considerable morphologic overlap of bone tumors with other mesenchymal …

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor
of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is …

Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are bone sarcomas with
intermediate malignant behavior and unpredictable prognosis. These locally aggressive …

Background Denosumab is a human monoclonal antibody (mAb) that specifically inhibits
tumor-associated bone lysis through the RANKL pathway and has been used as …

Background Although giant cell tumors (GCTs) are benign, their aggressiveness and
tendency to recur locally challenge the orthopaedic surgeon's ability to perform joint …

Background Denosumab is a monoclonal RANKL antibody, which was originally introduced
for the treatment of osteoporosis and bone metastases from solid tumors, but more recently …

Aims Denosumab, a human monoclonal antibody directed against the receptor activator of
nuclear factor‐κB ligand (RANKL), is a therapeutic agent for giant cell tumour of bone …

GCTB is an osteolytic, locally-aggressive, rarely-metastasizing tumour, characterized by
abundance of osteoclast-like giant cells, induced by neoplastic mononuclear cells …

Simple Summary Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone
tumor. Surgery remains the main treatment for GCTB. Denosumab has been approved for …

Simple Summary The overall clinical and cell biological behaviour of giant cell tumour of
bone still remains very difficult to understand. This entity is a prototype neoplasm illustrating …